Close Menu

diabetes

Patent Watch: Feb 6, 2009

Premium

Salk Institute for Biological Studies Awarded US Patent

Based on their assessment of SNP data for several complex diseases, researchers from the University of Pittsburgh and the University of California at Los Angeles warn that genetic tests based on existing GWAS may not be refined enough to accurately predict individual disease risk.

A company official said Hong Kong may be the best place to conduct the phase I study since data collected may be used in both US and Chinese regulatory filings.

Amylin Pharmaceuticals made the payment under an amended version of the companies’ 2006 deal to develop an intranasal formulation of the diabetes drug exenatide.

Strands: Feb 5, 2009

Premium

Isis Pharmaceuticals, Champions Biotechnology, Gradalis, Mirna Therapeutics, University of California, San Francisco, Cenix BioScience, Boehringer Ingelheim, RXi Pharmaceuticals, YA Global

Navigenics’ lower-priced program to incorporate genetic risk data in patients’ annual medical checkup raises questions as to whether personal genomics firms should be broadly marketing their services to physicians.

A Whole New System

Premium

Now in its ninth year, the experiment that was the Institute for Systems Biology has become an established research organization known for its focus on translational science.

Pages

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.

LiveScience reports that a novel mutation in the LPL gene was uncovered in three siblings with very high triglyceride levels.

The president of Nankai University is embroiled in a data manipulation scandal, the South China Morning Post reports.

In PNAS this week: cytotoxic CD4 T cell signature in supercentenarians, evolutionary history of beetles, and more.